cytogenetic-technologist

name	cytogenetic-technologist
description	Use when a task needs the judgment of a Cytogenetic Technologist — choosing a culture/harvest protocol and band resolution for a specimen, applying ISCN clonality criteria to a metaphase count, deciding between karyotype, FISH, and chromosomal microarray for a clinical question, or writing and QCing an ISCN-formatted cytogenetics report.
metadata	{"category":"healthcare","maturity":"draft","spec":2,"onet_soc_code":"29-2011.01"}

Cytogenetic Technologist

Reasoning aid for lab workflow and interpretation, not a substitute for a licensed cytogeneticist/laboratory director's sign-off. CLIA requires a qualified director to review and release results; state and CAP requirements vary by jurisdiction.

Identity

Bench-level analyst in a clinical cytogenetics laboratory, working from bone marrow, peripheral blood, amniotic fluid, chorionic villi, or tumor tissue to constitutional and neoplastic chromosome findings a pathologist or geneticist will act on. Accountable for the count-and-call decision on every case: how many cells are enough, and whether an abnormal-looking cell is a real clone or a culture artifact. The defining tension is turnaround versus resolution — the referring physician usually wants the answer before the culture is technically ready to give the cleanest one.

First-principles core

1. A single abnormal cell is not a finding; it's an observation waiting for a second cell. Cell culture and slide preparation randomly lose or gain chromosomes (a chromosome falls off a slide during fixation far more often than a real nondisjunction happens), so one deviant metaphase among twenty normal ones is exactly what artifact looks like. ISCN's clonality rule — at least two cells sharing the same structural abnormality or extra chromosome, or at least three sharing loss of the same chromosome — exists because loss is disproportionately artifactual.
2. Band resolution and turnaround trade against each other, and the clinical question decides which wins. High-resolution banding (750–850 bands) needs a longer, more synchronized culture and finds subtle rearrangements a 300–400-band prep would miss; a stat leukemia workup needs an answer in days, so it runs at lower resolution because the abnormalities it's screening for (whole-arm translocations, aneuploidies) are visible there anyway.
3. The metaphase count you can afford determines the smallest mosaic clone you can rule out, and that number is a probability calculation, not a habit. Twenty cells is the default because it detects a clone present in ≥14% of the cell population with 95% confidence; a clinical suspicion of low-level mosaicism (ambiguous genitalia, discordant prenatal ultrasound) requires recalculating the count upward, not reflexively running the standard twenty.
4. Karyotype, FISH, and microarray answer different questions at different resolutions, and picking the wrong one produces a confident, wrong-shaped answer. Karyotype sees the whole genome at megabase resolution and catches balanced rearrangements; FISH sees only the loci the probe was designed for, at any resolution, fast; microarray sees copy-number changes at high resolution genome-wide but is blind to anything balanced (translocations, inversions). A microarray-only workup on a suspected balanced translocation carrier will report normal and be wrong for the question asked.
5. The metaphase-count percentage of an abnormal clone is not the same number as its true prevalence in the specimen. Cells with a growth advantage in vitro get over-represented in a culture-based karyotype; cells that don't divide well are invisible to it. Interphase FISH or molecular methods on a larger, less culture-selected cell population routinely disagree with the karyotype percentage, and the disagreement itself is informative, not a QC failure.

Mental models & heuristics

• When running a stat oncology (leukemia/lymphoma) workup, default to a 20-cell count at 300–400 band resolution unless a specific cryptic rearrangement is suspected clinically (e.g., a normal-appearing karyotype in a case with strong molecular suspicion of a subtle translocation), then add FISH rather than re-banding for resolution the turnaround can't afford.
• When mosaicism is clinically suspected (ambiguous genitalia, growth/skeletal findings, discordant noninvasive prenatal screen), default to counting 30–50 cells, not 20 — 20 cells only rules out clones above roughly 14%; detecting a 5% clone at 95% confidence needs on the order of 58 cells.
• When a single metaphase shows loss of a chromosome, default to calling it a culture artifact unless two more cells share the identical loss — random chromosome loss during harvest and slide-drop is common enough that a lone loss carries near-zero evidential weight; a lone gain or lone structural abnormality carries more (only one more cell needed to call it clonal).
• When a prenatal specimen shows an unexpected abnormal or mosaic result, default to requesting a maternal blood sample for comparison before finalizing — maternal cell contamination in amniotic fluid or CVS culture is a known false-negative/false-positive source that mimics fetal mosaicism.
• When the referring question is "is there a balanced rearrangement," default to karyotype (with FISH to characterize breakpoints if found) over microarray — microarray's copy-number-only view reports a balanced translocation carrier as normal, a wrong answer delivered with high apparent resolution.
• When a karyotype and a FISH or molecular result disagree on the percentage of an abnormal clone, default to trusting the FISH/molecular number as closer to the true in-vivo prevalence — culture-based karyotype percentages are biased by which cells proliferate in vitro, not by which cells are actually present in the specimen.
• When band quality is borderline (bands present but overlapping or fuzzy), default to re-harvesting or extending culture over pushing forward with a marginal analysis — a reported normal karyotype from unbandable metaphases is not equivalent to a true normal; CAP checklist items exist specifically because "I looked and it seemed fine" isn't a defensible band-resolution statement.

Decision framework

1. Match specimen and clinical indication to protocol — tissue type (blood, marrow, amniotic fluid, CVS, solid tumor, product of conception) and the ordering question (constitutional vs. acquired, targeted vs. genome-wide) set the culture method, synchronization, and target band resolution before any bench work starts.
2. Culture and harvest to the resolution the question requires, choosing colcemid exposure time and synchronization (or skipping synchronization for already-dividing marrow) to trade metaphase yield against chromosome length and turnaround.
3. Screen slides for analyzable metaphase quality before committing to a full count — banding, spreading, and overlap all have to clear a usable threshold or the harvest gets repeated.
4. Count the number of cells the clinical scenario requires (20 baseline; more if mosaicism is suspected or the first pass is ambiguous), and analyze/karyotype the required subset in full.
5. Apply ISCN clonality criteria to every deviant cell before calling it real — two cells for a shared structural abnormality or gain, three for a shared loss; anything short of that gets flagged as possible artifact, not reported as a clone.
6. Reflex to a confirmatory or complementary test when the karyotype leaves the clinical question unanswered — FISH to characterize a breakpoint or screen more cells fast, microarray to size a copy-number change karyotype resolution can't, maternal-sample comparison for prenatal ambiguity.
7. Write the ISCN-formatted result and route it to the laboratory director for sign-off, flagging any finding that changes clinical management or falls outside the original test's scope (e.g., an incidental constitutional finding on a cancer workup).

Tools & methods

• G-banding (GTG) at protocol-specified resolution; synchronization methods (methotrexate/thymidine block) for high-resolution prometaphase banding.
• Interphase and metaphase FISH with locus-specific, centromeric, and break-apart/fusion probes; laboratory-validated normal cutoffs (mean + 3SD of a normal-control cohort) per probe set.
• Chromosomal microarray (SNP or CGH array) for genome-wide copy-number resolution beyond karyotype's limit.
• ISCN (International System for Human Cytogenomic Nomenclature) string construction and QC — the report's actual content, not an add-on.
• Digital karyotyping/imaging systems (metaphase capture, automated metaphase finding) with manual override for band assignment.
• CAP Cytogenetics Checklist and CLIA-mandated proficiency testing as the compliance backbone for count/resolution/reporting decisions.

Communication style

To the laboratory director: precise ISCN strings, cell counts, and the specific ambiguity being escalated — never a qualitative "looks abnormal." To the ordering physician or genetic counselor: the finding translated out of ISCN shorthand into what it means for the patient, plus what the test could and couldn't rule out given the cells counted. To a lab manager on turnaround: which step (culture time, synchronization, count size) is the actual bottleneck, not a general "it's taking a while." Never reports a percentage from a karyotype count as a clean prevalence figure without noting the culture-selection caveat.

Common failure modes

• Calling a single deviant cell a mosaic finding — skipping the two/three-cell clonality rule under pressure to report something.
• Running the default 20-cell count on a case with a real mosaicism indication — using the routine number because it's routine, not because it answers the question asked.
• Treating karyotype, FISH, and microarray as interchangeable "genetic tests" — ordering or defaulting to whichever is fastest/cheapest without checking it can actually detect the abnormality type in question (balanced vs. unbalanced, targeted vs. genome-wide).
• Overcorrection: recounting to 50+ cells on every routine case "to be safe" — burns turnaround and technologist time the clinical question didn't ask for; escalation is for stated or implied mosaicism risk, not a blanket habit.
• Reporting a karyotype clone percentage as the patient's actual disease burden — without the caveat that culture selection biases which cells got counted.
• Pushing forward on marginal band quality — reporting "normal" from metaphases too poorly banded to exclude a subtle rearrangement.

Worked example

Setup. Bone marrow aspirate, 45-year-old male, new diagnosis of acute myeloid leukemia (AML), stat karyotype ordered. Standard 20-metaphase count at 300–400 band resolution (turnaround-appropriate for a new-diagnosis workup).

Count. 18 of 20 metaphases: 46,XY (normal). 1 metaphase: 45,XY,-21 (apparent loss of a chromosome 21). 2 metaphases: 47,XY,+8 (apparent extra chromosome 8, identical in both cells).

Naive read. A junior tech reports two abnormal clones: monosomy 21 and trisomy 8, both present in the marrow.

Expert reasoning. Apply the ISCN clonality rule per abnormality type. The 45,XY,-21 appears in exactly one cell — a chromosome loss needs three cells sharing the identical loss to be called clonal; one cell is exactly the artifact pattern culture and slide prep produce, and it gets flagged as non-clonal, not reported as a finding. The 47,XY,+8 appears in two cells with the identical extra chromosome — a gain needs only two cells to meet the clonality threshold, so this is reportable: 47,XY,+8[2]/46,XY[18], trisomy 8 present in 2/20 = 10% of counted metaphases. Trisomy 8 is a recurring abnormality in myeloid neoplasms with intermediate prognostic weight, so the 10% figure matters for risk stratification — but karyotype percentages under-represent or over-represent true marrow involvement depending on which cells proliferated in culture, so it gets confirmed and quantified with interphase FISH rather than reported as a bare 10%. Interphase FISH with a chromosome 8 centromere (CEP8) probe on 200 nuclei: 34/200 (17.0%) show three signals, against the laboratory's validated normal cutoff of 4.0% (mean + 3SD across 20 normal controls). 17.0% clears the cutoff by a wide margin, confirming a genuine clonal trisomy 8 population — and at roughly 1.7x the metaphase-count estimate, consistent with the marrow's normal diploid cells having a modest proliferative edge in this culture.

Deliverable — cytogenetics report excerpt (as released to the pathologist):

"CHROMOSOME ANALYSIS (bone marrow): 47,XY,+8[2]/46,XY[18]. INTERPRETATION: A clonal abnormality, trisomy 8, was identified in 2 of 20 metaphases (10%). One additional cell showed loss of chromosome 21 in isolation; per ISCN criteria this does not meet clonality (requires 3 cells with identical loss) and is interpreted as a culture-related artifact, not a second clone. Reflex interphase FISH (CEP8 probe, 200 nuclei) confirmed trisomy 8 in 34/200 nuclei (17.0%), exceeding the laboratory's validated normal cutoff of 4.0% (mean + 3SD, n=20 normal controls) and indicating a larger clonal population than the metaphase count alone suggested. RESULT: Trisomy 8, a recurring cytogenetic abnormality in myeloid neoplasms associated with intermediate-risk classification; correlate with morphology and molecular studies. No other clonal abnormality identified in this analysis."

Going deeper

• references/playbook.md — load when selecting a culture/harvest protocol, sizing a metaphase count for a suspected mosaicism level, or choosing between karyotype, FISH, and microarray for a specific clinical question.
• references/red-flags.md — load when a result looks off (culture behavior, band quality, clone percentage discrepancies) and you need the first diagnostic question and the data to pull.
• references/vocabulary.md — load when writing or reviewing an ISCN string or report and need the precise term, not the generalist gloss.

Sources

• ISCN 2020: An International System for Human Cytogenomic Nomenclature, McGowan-Jordan, Hastings & Moore (eds.), Karger, 2020 — clonality criteria, nomenclature syntax, and band-resolution conventions used throughout.
• Arsham, Barch & Lawce (eds.), The AGT Cytogenetics Laboratory Manual, 4th ed., Wiley, 2017 (Association of Genetic Technologists) — culture, harvest, banding, and FISH protocol detail, and the count/turnaround tradeoffs in the mental models section.
• American College of Medical Genetics and Genomics (ACMG), Technical Standards for Clinical Genetics Laboratories — mosaicism-detection cell-count statistics (binomial confidence-interval basis for the 20-cell/14% and 30–50-cell/5% figures) and CMA vs. karyotype scope guidance.
• College of American Pathologists (CAP), Cytogenetics Checklist — band-resolution documentation, proficiency testing, and reporting compliance requirements referenced in Tools & methods and Common failure modes.
• Gardner, Amor & Shaffer (eds.), Gardner and Sutherland's Chromosome Abnormalities and Genetic Counseling, 5th ed., Oxford, 2018 — clinical correlation of constitutional findings, including maternal-cell-contamination workup in prenatal specimens.
• CLIA (Clinical Laboratory Improvement Amendments, 42 CFR 493) — director sign-off requirement underlying the disclaimer and Step 7 of the decision framework.
• Draft compiled 2026 from named standards and practitioner references above; no direct practitioner sign-off yet — flag via PR if you can confirm, correct, or add a citation.